Eiger BioPharmaceuticals, Inc. (EIGR) financial statements (2021 and earlier)

Company profile

Business Address 2155 PARK BOULEVARD
PALO ALTO, CA 94306
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1299510042603314
Cash and cash equivalents29396132283314
Short-term investments10056391032  
Other undisclosed cash, cash equivalents, and short-term investments00     
Receivables     0 
Prepaid expense0    0 
Other undisclosed current assets85111174
Total current assets:13810010242613488
Noncurrent Assets
Operating lease, right-of-use asset12
Property, plant and equipment11000(0)1
Other noncurrent assets4300000
Other undisclosed noncurrent assets     0 
Total noncurrent assets:6510001
TOTAL ASSETS:14410510243613489
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1616105516
Accounts payable5663303
Accrued liabilities111042311
Employee-related liabilities     02
Interest and dividends payable      0
Other undisclosed accounts payable and accrued liabilities      (0)
Debt 1 2  0
Restructuring reserve     1 
Other undisclosed current liabilities1     1
Total current liabilities:1717107527
Noncurrent Liabilities
Long-term debt and lease obligation, including:32322613  10
Long-term debt, excluding current maturities31302613   
Operating lease, liability11
Other undisclosed long-term debt and lease obligation      10
Liabilities, other than long-term debt, including:  0  0 
Other liabilities  0    
Other undisclosed liabilities, other than long-term debt     0 
Other undisclosed noncurrent liabilities(1)   15 (10)
Total noncurrent liabilities:323226131500
Total liabilities:494936202027
Stockholders' equity
Stockholders' equity attributable to parent95566723413272
Common stock0000000
Additional paid in capital402298238141117222219
Accumulated other comprehensive income (loss)(0)0(0)(0)(0) (0)
Accumulated deficit(307)(241)(171)(119)(76)(191)(146)
Total stockholders' equity:95566723413272
Other undisclosed liabilities and equity      10
TOTAL LIABILITIES AND EQUITY:14410510243613489

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(62)(69)(51)(42)(46)(42)(33)
Operating loss:(62)(69)(51)(42)(46)(42)(33)
Nonoperating income (expense)1211(0)00
Investment income, nonoperating1210 00
Other nonoperating income (expense)(0)(0)(0)0(0)0(0)
Interest and debt expense(4)(3)(2)(2)(1)(2)(1)
Loss before gain (loss) on sale of properties:(65)(70)(52)(42)(47)(44)(34)
Other undisclosed net loss      (0)
Net loss available to common stockholders, diluted:(65)(70)(52)(42)(47)(44)(34)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(65)(70)(52)(42)(47)(44)(34)
Other comprehensive loss      (34)
Comprehensive loss:(65)(70)(52)(42)(47)(44)(68)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)0(0)0 
Comprehensive loss, net of tax, attributable to parent:(65)(70)(52)(42)(47)(44)(68)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: